| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
SPNE Stock Overview
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally.
SeaSpine Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.46 |
| 52 Week High | US$17.34 |
| 52 Week Low | US$5.54 |
| Beta | 1.39 |
| 1 Month Change | 30.65% |
| 3 Month Change | -9.90% |
| 1 Year Change | -49.32% |
| 3 Year Change | -32.24% |
| 5 Year Change | -34.27% |
| Change since IPO | -64.48% |
Recent News & Updates
SeaSpine amends $30M credit facility
SeaSpine (NASDAQ:SPNE) said Tuesday it amended its credit facility to extend its maturity date to Jul. 27, 2025 from Jul. 27, 2022. SPNE also has the option to increase the existing $30M borrowing limit by up to an additional $10M. "The additional liquidity provided by this facility will directly support new product launches across all portfolios," said SPNE COO and CFO John Bostjancic.
Shareholder Returns
| SPNE | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 9.1% | -0.4% | 1.4% |
| 1Y | -49.3% | -21.3% | -8.4% |
Return vs Industry: SPNE underperformed the US Medical Equipment industry which returned -21.1% over the past year.
Return vs Market: SPNE underperformed the US Market which returned -9% over the past year.
Price Volatility
| SPNE volatility | |
|---|---|
| SPNE Average Weekly Movement | 6.7% |
| Medical Equipment Industry Average Movement | 9.5% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SPNE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SPNE's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 523 | Keith Valentine | https://www.seaspine.com |
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company’s orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures.
SeaSpine Holdings Fundamentals Summary
| SPNE fundamental statistics | |
|---|---|
| Market Cap | US$277.42m |
| Earnings (TTM) | -US$66.96m |
| Revenue (TTM) | US$209.05m |
1.3x
P/S Ratio-4.1x
P/E RatioIs SPNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPNE income statement (TTM) | |
|---|---|
| Revenue | US$209.05m |
| Cost of Revenue | US$79.07m |
| Gross Profit | US$129.98m |
| Other Expenses | US$196.94m |
| Earnings | -US$66.96m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.80 |
| Gross Margin | 62.18% |
| Net Profit Margin | -32.03% |
| Debt/Equity Ratio | 8.7% |
How did SPNE perform over the long term?
See historical performance and comparisonValuation
Is SPNE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SPNE?
Other financial metrics that can be useful for relative valuation.
| What is SPNE's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$277.42m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | -5.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SPNE's PS Ratio compare to its peers?
| SPNE PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.7x | ||
APEN Apollo Endosurgery | 3.7x | 26.1% | US$251.8m |
SRTS Sensus Healthcare | 5.2x | 13.0% | US$214.6m |
EDAP EDAP TMS | 5.2x | 16.1% | US$244.6m |
ARAY Accuray | 0.6x | 4.9% | US$270.2m |
SPNE SeaSpine Holdings | 1.3x | 12.4% | US$277.4m |
Price-To-Sales vs Peers: SPNE is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (3.7x).
Price to Earnings Ratio vs Industry
How does SPNE's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: SPNE is good value based on its Price-To-Sales Ratio (1.3x) compared to the US Medical Equipment industry average (4.4x)
Price to Sales Ratio vs Fair Ratio
What is SPNE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.3x |
| Fair PS Ratio | 2.9x |
Price-To-Sales vs Fair Ratio: SPNE is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (2.9x).
Share Price vs Fair Value
What is the Fair Price of SPNE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SPNE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SPNE's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Future Growth
How is SeaSpine Holdings forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score
1/6Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
16.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SPNE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SPNE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SPNE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SPNE's revenue (12.4% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: SPNE's revenue (12.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SPNE's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has SeaSpine Holdings performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-12.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SPNE is currently unprofitable.
Growing Profit Margin: SPNE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SPNE is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare SPNE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPNE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).
Return on Equity
High ROE: SPNE has a negative Return on Equity (-23.35%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is SeaSpine Holdings's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SPNE's short term assets ($190.0M) exceed its short term liabilities ($54.4M).
Long Term Liabilities: SPNE's short term assets ($190.0M) exceed its long term liabilities ($44.3M).
Debt to Equity History and Analysis
Debt Level: SPNE has more cash than its total debt.
Reducing Debt: SPNE's debt to equity ratio has increased from 3.7% to 8.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SPNE has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SPNE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 25.1% each year
Discover healthy companies
Dividend
What is SeaSpine Holdings's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SPNE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SPNE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SPNE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SPNE's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SPNE has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
5.7yrs
Average management tenure
CEO
Keith Valentine (54 yo)
7.25yrs
Tenure
US$2,093,155
Compensation
Mr. Keith C. Valentine serves as Non-Executive Chair of the Board at Locate Bio Limited since January 5, 2021. He has been the Chief Executive Officer of SeaSpine Holdings Corporation since May 2015 and ha...
CEO Compensation Analysis
Compensation vs Market: Keith's total compensation ($USD2.09M) is about average for companies of similar size in the US market ($USD1.67M).
Compensation vs Earnings: Keith's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: SPNE's management team is seasoned and experienced (5.7 years average tenure).
Board Members
Experienced Board: SPNE's board of directors are considered experienced (7.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.
Top Shareholders
Company Information
SeaSpine Holdings Corporation's employee growth, exchange listings and data sources
Key Information
- Name: SeaSpine Holdings Corporation
- Ticker: SPNE
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$277.421m
- Shares outstanding: 37.19m
- Website: https://www.seaspine.com
Number of Employees
Location
- SeaSpine Holdings Corporation
- 5770 Armada Drive
- Carlsbad
- California
- 92008
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/18 00:00 |
| End of Day Share Price | 2022/08/18 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.